Gene therapy for childhood immunological diseases

Bone Marrow Transplantation

Volumn 41, Issue 2, 2008, Pages 199-205

  Kohn, D B ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; IMMUNOSUPPRESSIVE AGENT; LENTIVIRUS VECTOR; MACROGOL; PEGADEMASE; RETROVIRUS VECTOR;

ADENOSINE DEAMINASE DEFICIENCY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CHILD; CHILDHOOD DISEASE; CHRONIC GRANULOMATOUS DISEASE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINED IMMUNODEFICIENCY; DRUG POTENCY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; GENE THERAPY; GENETIC TRANSFECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOPATHOLOGY; INTERMETHOD COMPARISON; LEUKOCYTE ADHESION DEFICIENCY; LYMPHOPROLIFERATIVE DISEASE; NEUTROPENIA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; REVIEW; VIRAL GENE DELIVERY SYSTEM; WISKOTT ALDRICH SYNDROME; X CHROMOSOME LINKED DISORDER;

ANTIGENS, CD34; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFANT; TRANSPLANTATION, HOMOLOGOUS;

EID: 38849134812     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705895     Document Type: Review

References (42)

1. Gatti RA, Meuwissen HJ, Allen HD, Hong R, Good RA. Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet 1968; 2: 1366-1369.
2. Buckley RH, Schiff SE, Schiff RI, Markert L, Williams LW, Roberts JL et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunode.ciency. N Engl J Med 1999; 340: 508-516.
3. Haddad E, Landais P, Friedrich W, Gerritsen B, Cavazzana-Calvo M, Morgan G et al. Long-term immune reconstitution and outcome after HLA-nonidentical T-cell depleted bone marrow transplantation for severe combined immunodeficiency: A European retrospective. Blood 1998; 91: 3646-3653.
4. Antoine C, Muller S, Cant A, Cavazzana-Calvo M, Veys P, Vossen J et al. Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: Report of the European experience 1968-99. Lancet 2003; 361: 553-560.
5. Grunebaum E, Mazzolari E, Porta F, Dallera D, Atkinson A, Reid B et al. Bone marrow transplantation for severe combined immune deficiency. JAMA 2006; 295: 508-518.
6. Nolta JA, Kohn DB. Comparison of the effects of growth factors on retroviral vector-mediated gene transfer and the proliferative status of human hematopoietic progenitor cells. Hum Gene Ther 1990; 1: 257-268.
7. Mazurier F, Gan OI, McKenzie JL, Doedens M, Dick JE. Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment. Blood 2004; 103: 545-552.
8. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M et al. T lymphocyte-directed gene therapy for ADASCID: Initial trial results after 4 years. Science 1995; 270: 475-480.
9. Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P et al. Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 1995; 270: 470-475.
10. Onodera M, Ariga T, Kawamura N, Kobayashi I, Otsu M, Yamada M et al Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. Blood 1998; 91: 30-36.
11. Hoogerbrugge PM, van Beusechem VW, Fisher A, Debree M, leDeist F, Perignon JL et al. Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Therapy 1996; 3: 179-183.
12. Kohn DB, Weinberg KI, Nolta JA, Heiss LN, Lenarsky C, Crooks GM et al Engraftment of gene-modified cells from umbilical cord blood in neonates with adenosine deaminase deficiency. Nat Med 1995; 1 1017-1026.
13. Aiuti A, Vai S, Mortellaro A, Casorati G, Ficara F, Andolfi G et al Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement. Nat Med 2002; 8: 423-425.
14. Kohn DB, Hershfield MS, Carbonaro D, Shigeoka A, Brooks J, Smogorzewska EM et al. T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonates. Nat Med 1998; 4: 775-780.
15. Chan B, Wara D, Bastian J, Hershfield MS, Azen C, Parkman R et al. Long term efficacy of polyethylene glycol modified adenosine deaminase (PEG-ADA) enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immune de.ciency (SCID). Clin Immunol 2005; 117: 133-143.
16. Dao MA, Hannum CH, Kohn DB, Nolta JA. Flt3 ligand preserves the ability of human CD34+ progenitors to sustain long-term hematopoiesis in immune-deficient mice after ex vivo retroviral-mediated transduction. Blood 1997; 89: 446-456.
17. Hanenberg H, Xiao XL, Dilloo D, Hashino K, Kato I, Williams DA. Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. Nat Med 1996; 2: 876-882.
18. Wu T, Kim HJ, Sellers SE, Meade KE, Agricola BA, Metzger ME et al. Prolonged high-level detection of retrovirally marked hematopoietic cells in nonhuman primates after transduction of CD34+ progenitors using clinically feasible methods. Mol Ther 2000; 1: 285-293.
19. Aiuti A, Slavin S, Aker M, Ficara F, Deola S, Mortellaro A et al. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning. Science 2002; 296: 2410-2413.
20. Gaspar HB, Bjorkegren E, Parsley K, Gilmour KC, King D, Sinclair J et al. Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADAand use of mild preconditioning. Mol Ther 2006; 14: 505-513.
21. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000; 288: 669-672.
22. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346: 1185-1193.
23. Gaspar HB, Parsley KL, Howe S, King D, Gilmour KC, Sinclair J et al Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector. Lancet 2004; 364: 2181-2187.
24. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302 415-419.
25. Wu X, Li Y, Crise B, Burgess SM. Transcription start regions in the human genome are favored targets for MLV integration. Science 2003; 300: 1749-1751.
26. Bushman FD. Retroviral integration and human gene therapy. J Clin Invest 2007; 117: 2083-2086.
27. Deichmann A, Hacein-Bey-Abina S, Schmidt M, Garrigue A, Brugman MH, Hu J et al. Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. J Clin Invest 2007; 117: 2225-2232.
28. Aiuti A, Cassani B, Andol. G, Mirolo M, Biasco L, Recchia A et al. Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. J Clin Invest 2007; 117: 2233-2240.
29. Schwarzwaelder K, Howe SJ, Schmidt M, Brugman MH, Deichmann A, Glimm H et al. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo. J Clin Invest 2007; 117: 2241-2249.
30. Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science 2004; 303: 333.
31. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U et al Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006; 12: 401-409.
32. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
33. May C, Rivella S, Callegari J, Heller G, Gaensler KM, Luzzatto L et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000; 406: 82-86.
34. Hanawa H, Hematti P, Keyvanfar K, Metzger ME, Krouse A, Donahue RE et al. Efficient gene transfer into rhesus repopulating hematopoietic stem cells using a Simian immunodeficiency virus-based lentiviral vector system. Blood 2004; 103: 4062-4069.
35. Levine BL, Humeau LM, Boyer J, Macgregor RR, Rebello T, Lu X et al Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006; 103: 17372-17377.
36. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse modeluncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 2006; 24: 687-696.
37. Josephson NC, Vassilopoulos G, Trobridge GD, Priestley GV, Wood BL, Papayannopoulou T et al. Transduction of human NOD/ SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors. Proc Natl Acad Sci USA 2002; 99: 8295-8300.
38. Bauer Jr TR, Hai M, Tuschong LM, Burkholder TH, Gu YC, Sokolic RA et al. Correction of the disease phenotype in canine leukocyte adhesion deficiency using ex vivo hematopoietic stem cell gene therapy. Blood 2006; 108: 3313-3320.
39. Hackett PB, Ekker SC, Largaespada DA, McIvor RS. Sleeping beauty transposon-mediated gene therapy for prolonged expression. Adv Genet 2005; 54: 189-232.
40. Thyagarajan B, Olivares EC, Hollis RP, Ginsburg DS, Calos MP. Site-specific genomic integration in mammalian cells mediated by phage phiC31 integrase. Mol Cell Biol 2001; 21: 3926-3934.
41. Hollis RP, Nightingale SJ, Pepper KA, Yu XJ, Barsky L, Crooks GM et al. Stable gene transfer to human CD34+ hematopoietic progenitor cells using the sleeping beauty transposon. Exp Hematol 2006; 34: 1333-1343.
42. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S et al Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435: 646-651.